论文部分内容阅读
目的:探讨糖尿病与良性前列腺增生(BPH)发生和进展的相关性。方法:对临床明确诊断BPH 190例患者的临床资料进行分组对比分析。结果:190例患者中,单纯BPH组100例,BPH合并糖尿病者90例(47.4%)。BPH合并糖尿病组患者的国际前列腺症状评分(IPSS)明显大于单纯BPH组[(23.72±6.08)分比(21.49±7.83)分,P<0.05],最大尿流率(Qmax)明显小于单纯BPH组[(8.0±4.6)ml/s比(9.9±5.3)ml/s,P<0.05]。在BPH患者中,空腹血糖异常组患者的IPSS[(24.07±4.73)分比(22.34±5.12)分]、前列腺体积[(75.41±58.36)ml比(72.04±40.49)ml]明显大于空腹血糖正常组(P<0.05);而餐后正常血糖组与餐后异常血糖组各指标比较均无显著性差异(P均>0.05)。与单纯BPH组相比,BPH合并糖尿病组的不同糖尿病病程患者的BPH各指标无显著性差异(P均>0.05)。结论:良性前列腺增生同时合并糖尿病多见;糖尿病尤其异常空腹血糖水平可促进良性前列腺增生的发生以及进展。
Objective: To investigate the relationship between diabetes and benign prostatic hyperplasia (BPH). Methods: The clinical data of 190 patients with clinically definite diagnosis of BPH were grouped and analyzed comparatively. Results: Of the 190 patients, 100 were BPH alone and 90 (47.4%) were BPH patients with diabetes mellitus. The International Prostate Symptom Score (IPSS) in BPH patients with diabetes mellitus was significantly higher than that in BPH patients [(23.72 ± 6.08) vs (21.49 ± 7.83), P <0.05], and the maximum flow rate (Qmax) [(8.0 ± 4.6) ml / s ratio (9.9 ± 5.3) ml / s, P <0.05]. In patients with BPH, IPSS [(24.07 ± 4.73) min (22.34 ± 5.12) min] and prostate volume [(75.41 ± 58.36) ml (72.04 ± 40.49) ml] were significantly higher than those in patients with fasting plasma glucose Group (P <0.05). However, there was no significant difference between the postprandial normal glucose group and the postprandial abnormal blood glucose group (all P> 0.05). Compared with the BPH group alone, there was no significant difference in each index of BPH between BPH and diabetic group (all P> 0.05). Conclusion: Benign prostatic hyperplasia with diabetes mellitus more common; Diabetes, especially abnormal fasting blood glucose levels can promote the occurrence and progress of benign prostatic hyperplasia.